相关实验视频
Updated: Jul 4, 2025
09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
2.7K
凝血素作为预防急性冠状动脉综合征后复发事件的标
M Cecilia Bahit1, C Michael Gibson2
1INECO Neurociencias, Rosario, Provincia de Santa Fe, Argentina.
Thrombosis research
|February 9, 2024
概括
血栓素在急性冠状动脉综合征 (ACS) 血栓形成和复发事件中发挥着关键作用. 向血素,就像抑制XI因子一样,可以减少ACS后的心血管事件,同时保持血液静止.
科学领域:
- 心血管医学 心血管医学
- 血液学 血液学 血液学
- 血栓形成的研究研究
背景情况:
- 在急性冠状动脉综合征 (ACS) 中,血栓形成涉及血小板和血栓.
- 血小板抑制在慢性ACS治疗中很常见,但血小板激活和纤维素形成中,血栓是至关重要的.
- ACS患者表现出持续的慢性血栓生成,与不良事件相关.
研究的目的:
- 审查关于在ACS后复发事件中产生血栓的证据.
- 评估血栓素作为ACS管理中的治疗标.
- 探索XI因子抑制作为一种潜在的策略.
主要方法:
- 对血栓生成和ACS病理生理学研究的文献综述.
- 对ACS后护理中抗血栓治疗的临床试验数据的分析.
- 检查XI因子在血栓生成和血液静止中的作用.
主要成果:
- 血生成与ACS后的复发性心血管事件有关.
- 向用Rivaroxaban或Vorapaxar等药物向血素可以减少事件,但会增加出血.
- 抑制XI因子是减少血栓生成的潜在目标,同时保持血静.
结论:
- 血生成是ACS后复发事件的一个重要因素.
- 向血栓通路提供了潜在的好处,但需要仔细评估风险-好处.
- 抑制XI因子是一种有前途的治疗策略,可以通过调节血栓生成来控制ACS,从而可能保持血静.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
01:16Clot Retraction and Fibrinolysis
5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
524
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
524
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
01:22Formation of the Platelet Plug
6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K